Dr. Reddy’s subsidiary, Dr. Reddy’s SA, has noted that its partner, Immutep, has halted enrollment in the TACTI-004 Phase III trial evaluating Eftilagimod alfa (‘efti’) for non-small cell lung cancer. An Independent Data Monitoring Committee recommended discontinuation following an interim futility analysis based on safety and efficacy data. Dr. Reddy’s SA has made only the initial upfront payment and is engaging with Immutep on next steps for the program.
Update on Eftilagimod Alfa Development
Dr. Reddy’s Laboratories Ltd. provided an update regarding the strategic collaboration and exclusive licensing agreement involving its wholly-owned subsidiary, Dr. Reddy’s SA, and Immutep SAS (a subsidiary of Immutep Limited). This agreement covers the development and commercialization of Eftilagimod alfa (‘efti’) outside of North America, Europe, Japan, and Greater China.
Phase III Trial Recommendation
The company confirmed that Immutep announced on March 13, 2026, that the Independent Data Monitoring Committee (IDMC) for the TACTI-004 Phase III study has recommended the discontinuation of the trial. This recommendation pertained to the first-line non-small cell lung cancer indication and followed a planned interim futility analysis based on available safety and efficacy data.
Study Wind-Down and Next Steps
In response to the IDMC’s findings, Immutep will halt enrolment immediately and implement an orderly wind-down of the study, ensuring appropriate patient follow-up and site close-out according to regulatory requirements. Immutep is currently conducting a comprehensive review of the data to determine the appropriate future strategy for the Eftilagimod alfa program.
Financial Implications for Dr. Reddy’s
Dr. Reddy’s SA has confirmed that, to date, it has only remitted the upfront payment to Immutep. The company remains engaged with Immutep to discuss the way forward. Immutep has reaffirmed its commitment to advancing its pipeline, which includes Eftilagimod Alfa.
Source: BSE
